

# **Analysis of proliferating neuronal progenitors and immature neurons in the human hippocampus surgically removed from control and epileptic patients**

Tatsunori Seki<sup>1,2\*</sup>, Tomokatsu Hori<sup>3,4</sup>, Hajime Miyata<sup>5</sup>, Michiyo Maehara<sup>4,6</sup>, and Takashi Namba<sup>2,7</sup>

<sup>1</sup>Department of Histology and Neuroanatomy, Tokyo Medical University, Tokyo 160-8402, Japan

<sup>2</sup>Department of Anatomy, Juntendo University School of Medicine, 113-8421 Tokyo Japan

<sup>3</sup>Department of Neurosurgery, Tokyo Neurological Center Hospital, Tokyo 134-0088, Japan

<sup>4</sup>Department of Neurosurgery, Tokyo Women's Medical University, Tokyo 162-8666, Japan

<sup>5</sup>Department of Neuropathology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan

<sup>6</sup>Central Clinical Laboratory, Tokyo Women's Medical University, Tokyo 162-8666, Japan

<sup>7</sup>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden 01307, Germany

**\*Corresponding author:**

Tatsunori Seki, Ph.D.

Department of Histology and Neuroanatomy


Tokyo Medical University

6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan


Phone: +81-(0)3-3351-6141 (ext. 274)

Fax: +81-(0)3-3351-7886

Email: [sekit@tokyo-med.ac.jp](mailto:sekit@tokyo-med.ac.jp)




**Supplemental Figure 1.** Nissl staining of the hippocampal formation. The proximal tip of the CA3 pyramidal cell layer bends and forms the so-called end blade or CA4, and similar-looking large neurons are observed in both the CA4 and the CA3 regions. The hilus (also called polymorphic layer, PL) is located between the granule cell layer (GCL) and CA4, and appears to contain fewer number of large neurons, compared with CA4. In Figure 4, PSA-NCAM+ cells were counted in the hSGA (see Supplemental Figure 2) and an area enclosed by the C-shaped GCL consisting of the hilus and a part of the CA3 pyramidal cell layer (GCL-enclosed area, demarcated by a dashed line), because unlike the rodent hippocampus, in humans, PSA-NCAM+ cells are distributed in the entire GCL-enclosed area, and it is sometimes difficult to differentiate cells of the hilus from CA4 cells. Scale bar = 1 mm




**Supplemental Figure 2.** Comparison between the rat subgranular zone (SGZ) (A) and the human subgranular area (hSGA) (B) using Nissl staining (A1, B1) and PSA-NCAM immunostaining (A2, B2). In rats, PSA-NCAM+ cells are confined to the narrow band below the granule cell layer (GCL), the so-called SGZ, whereas in humans, PSA-NCAM+ cells are distributed in a broad band below the GCL and also in the hilar region. For this reason, we refer to the putative human SGZ as the human subgranular area (hSGA), to avoid confusion with the narrow and distinct SGZ of rodents. In the present study, the hSGA was tentatively defined as a 50- $\mu$ m wide region below the GCL (indicated by dashed lines), because the density of round or spindle-shaped cells resembling rodent neural progenitor cells was high compared with the lower area. Scale bars = 50  $\mu$ m in A and B.





**Supplemental Figure 3.** (A) PSA-NCAM and GFAP immunohistochemistry in the hilus of an epileptic patient (EP9, see Supplemental Table 1). A PSA-NCAM+ aberrant cell (arrow) is negative for GFAP. (B) PSA-NCAM and GAD65 immunohistochemistry in the hilus of an epileptic patient (EP1). Z-stack images (B1 – 3) were reconstructed from 20 optical slices. GAD65+ terminals are distributed in the soma (arrow) and processes (arrowheads) of a PSA-NCAM+ aberrant cell, suggesting that PSA-NCAM+ aberrant cells are integrated into hippocampal neuronal circuits. Scale bars = 50  $\mu$ m in A and B.



**Supplemental Figure 4.** Comparison of PSA-NCAM, DCX, and Ki67 immunostaining with or without citrate buffer pretreatment for antigen retrieval. Z-stack images of B4 and C4 were reconstructed from 10 and 21 optical slices, respectively. **(A)** Pretreatment with citrate buffer restored Ki67 immunoreactivity, but abolished PSA-NCAM immunoreactivity (arrows). **(B – C)** Comparison of the distribution of PSA-NCAM<sup>+</sup> and DCX<sup>+</sup> cells (arrows) without citrate buffer pretreatment. Images A and B were obtained from control patient CN2, and image C was from control patient CN3 (see Supplemental Table 1). Scale bars = 100  $\mu$ m in B; 50  $\mu$ m in A and C

Supplementary table 1.

| Case No.                                    | Gender | age at surgery | Onset | side of resection | HS types* | Clinical History and Others     |
|---|--------|----------------|-------|-------------------|-----------|---------------------------------|
| <b>Control</b>                              |        |                |       |                   |           |                                 |
| CN1   | M      | 16             |       | left              |           | glioma (fibrillary astrocytoma) |
| CN2   | M      | 30             |       | right             |           | glioma                          |
| CN3   | M      | 33             |       | left              |           | glioma                          |
| CN4   | M      | 44             |       | left              |           | glioblastoma                    |
| CN5   | M      | 49             |       | right             |           | cavernous angioma               |
| CN6   | M      | 49             |       | right             |           | astrocytoma                     |
| <b>Patients with temporal lobe epilepsy</b> |        |                |       |                   |           |                                 |
| mild granule cell dispersion                |        |                |       |                   |           |                                 |
| EP1   | F      | 9              |       | right             |           | Rasmussen encephalitis          |
| EP2   | M      | 17             |       | right             |           |                                 |
| EP3   | F      | 29             |       | right             | Type 2    |                                 |
| EP4   | M      | 34             |       | left              |           |                                 |
| EP5   | M      | 37             | 22    | right             |           |                                 |
| EP6   | M      | 43             | 16    | right             |           |                                 |
| sever granule cell dispersion               |        |                |       |                   |           |                                 |
| EP7   | F      | 19             | 7     | left              | Type 1    |                                 |
| EP8   | M      | 35             | 10 mo | left              | Type 3    |                                 |
| EP9   | M      | 36             | 8     | left              | Type 1    |                                 |
| EP10  | M      | 40             | 32    | left              | Type 1    |                                 |
| EP11  | M      | 42             | 4-5   | right             | Type 1    | used only in PSA-NCAM analysis  |
| EP12  | F      | 21             | 9     | left              | N.D.      | used only in Ki67 analysis      |

Age of patients at surgery and onset of seizures is given in months (mo) or years. \*The International League Against Epilepsy classifies hippocampal sclerosis (HS) into three types. Type 1 refers to severe neuronal cell loss and gliosis predominantly in the CA1 and CA4 regions, compared with CA1-predominant neuronal cell loss and gliosis (HS ILAE type 2), or CA4-predominant neuronal cell loss and gliosis (HS ILAE type 3)<sup>1</sup>. Control patient CN3 had a single seizure. N.D.: not determined

1. Blumcke I, Thom M, Aronica E, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the ILAE Commission on Diagnostic Methods. *Epilepsia* 54:1315-1329 (2013).

Supplementary table 2. List of antibodies

used in this study

|                              | Species/Class  | Dilution  | Source                                       | Catalog number |
|------------------------------|----------------|-----------|--|----------------|
| <b>Primary antibody</b>      |                |           |  |                |
| DCX                          | Guinea pig IgG | 1 : 400   | Chemicon (Merck,Darmstadt, Germany)          | AB5910         |
| DCX (C-18)                   | Goat IgG       | 1 : 400   | Santa Cruz (Dallas, TX, USA)                 | sc-8066        |
| GAD65                        | Mouse IgG      | 1 : 200   | Sigma (Merck, Darmstadt, Germany)            | G1166          |
| GFAP                         | Mouse IgG      | 1 : 200   | Sigma (Merck, Darmstadt, Germany)            | G3893          |
| HuB (HEL-N1)                 | Rabbit IgG     | 1 : 400   | Sigma (Merck, Darmstadt, Germany)            | H-1538         |
| Ki67 (MIB-1)                 | Mouse IgG      | 1 : 500   | DAKO (Santa Clara, CA, USA)                  | M7240          |
| PSA-NCAM (12E3)              | Mouse IgM      | 1 : 1,000 | Seki and Arai, 1991 <sup>52</sup>            |                |
| <b>Secondary antibody</b>    |                |           |  |                |
| Goat IgG + Cy2               | Donkey         | 1 : 200   | Jackson ImmunoResearch (West Grove, PA, USA) | 705-225-147    |
| Guinea pig IgG + Cy3         | Donkey         | 1 : 200   | Jackson ImmunoResearch (West Grove, PA, USA) | 706-166-148    |
| Mouse IgG + Cy3              | Donkey         | 1 : 200   | Jackson ImmunoResearch (West Grove, PA, USA) | 715-165-151    |
| Mouse IgG + Cy5              | Donkey         | 1 : 200   | Jackson ImmunoResearch (West Grove, PA, USA) | 715-175-151    |
| Mouse IgM ( $\mu$ ) + Cy2    | Goat           | 1 : 200   | Jackson ImmunoResearch (West Grove, PA, USA) | 115-225-075    |
| Mouse IgM ( $\mu$ ) + biotin | Goat           | 1 : 200   | Vectastain (Burlingame, CA, USA)             | BA-2020        |